Novavax gets EU authorization for updated COVID-19 vaccine
by
Contributor since / Followers
Contributor since / Followers
5 months ago
Kittisak Kaewchalun
- Novavax (NASDAQ:NVAX) has received marketing authorization from the European Commission for its updated 2024-2025 Nuvaxovid COVID-19 vaccine for use in people aged 12 years and older.
- Novavax said the updated vaccine provides cross-reactivity against the JN.1 and numerous JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1, according to a statement.
- The vaccine is also authorized for use in the U.S. under an FDA emergency use authorization.
- Other leading makers of COVID-19 vaccines include Moderna (MRNA) and partners Pfizer (PFE) and BioNTech (BNTX).